Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.40 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HMGCR | P04035 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | CTH | P32929 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | LDHA | P00338 | 1/20 | 0.33 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL986001 | 0.80 | EGLN1 (0.38) | EGLN1FFAR3ALDH1A1TDP1HDAC3 | |
| SCHEMBL14420949 | 0.76 | FFAR3 (0.40) | EGLN1FFAR3ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL983535 | 0.75 | FFAR3 (0.35) | EGLN1FFAR3ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL162904 | 0.74 | DPP4 (0.40) | EGLN1FFAR3ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL26142062 | 0.73 | MAPT (0.39) | EGLN1ALDH1A1CYP2D6SMN1; SMN2HMGCR | |
| SCHEMBL242144 | 0.72 | — | — | |
| SCHEMBL10799064 | 0.72 | — | — | |
| SCHEMBL2590837 | 0.72 | FFAR3 (0.36) | EGLN1FFAR3ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL421124 | 0.72 | ALDH1A1 (0.40) | EGLN1FFAR3ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL345431 | 0.72 | FFAR3 (0.36) | EGLN1FFAR3ALDH1A1CYP2D6SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732382-B2 | Cross-linking composition and method of use | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-06-08 | — | — | US | claimed |
| WO-2007095367-A2 | CROSS-LINKING COMPOSITION AND METHOD OF USE | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2007-08-23 | — | — | WO | claimed |
| US-20070187102-A1 | Hydraulic fracturing methods using cross-linking composition comprising delay agent | E. I. DU PONT DE NEMOURS AND COMPANY | 2007-08-16 | — | — | US | claimed |
| US-20070191233-A1 | Cross-linking composition and method of use | DORF KETAL SPECIALITY CATALYSTS, LLC | 2007-08-16 | — | — | US | claimed |
| US-20070187642-A1 | Zirconium cross-linking composition and methods of use | E. I. DU PONT DE NEMOURS AND COMPANY | 2007-08-16 | — | — | US | claimed |
| US-20230295195-A1 | ANTIMICROBIAL ORGANOSILANES | Tipikos Pharmaceuticals, Inc. (US) | 2023-09-21 | — | — | US | disclosed |
| CN-110036343-B | Water-soluble composition, pattern forming agent, method for producing cured product using same, and cured product | 株式会社ADEKA | 2023-06-13 | — | — | CN | disclosed |
| CN-110337454-B | Water-soluble composition, method for producing cured product thereof, and acylphosphinate | 株式会社ADEKA | 2022-04-12 | — | — | CN | disclosed |
| CN-109312135-B | Water-soluble composition and cured product comprising same | 株式会社ADEKA | 2021-07-06 | — | — | CN | disclosed |
| CN-112384538-A | Polymer, composition containing same, method for curing same, cured product thereof, and method for producing polymer | 株式会社ADEKA | 2021-02-19 | — | — | CN | disclosed |
| WO-2020040094-A1 | POLYMER, COMPOSITION CONTAINING SAME, CURING METHOD THEREFOR, CURED PRODUCT THEREOF, AND POLYMER MANUFACTURING METHOD | 株式会社ADEKA | 2020-02-27 | — | — | WO | disclosed |
| EP-1984471-B1 | ZIRCONIUM CROSS-LINKING COMPOSITION AND METHODS OF USE | DORF KETAL SPECIALITY CAT LLC (US) | 2018-08-08 | — | — | EP | disclosed |
| WO-2007095367-A2 | CROSS-LINKING COMPOSITION AND METHOD OF USE | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2007-08-23 | — | — | WO | disclosed |
| WO-2007095018-A2 | ZIRCONIUM CROSS-LINKING COMPOSITION AND METHODS OF USE | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2007-08-23 | — | — | WO | disclosed |
| US-20070187098-A1 | Permeable zone and leak plugging using cross-linking composition comprising delay agent | E. I. DU PONT DE NEMOURS AND COMPANY | 2007-08-16 | — | — | US | disclosed |
| US-20070187102-A1 | Hydraulic fracturing methods using cross-linking composition comprising delay agent | E. I. DU PONT DE NEMOURS AND COMPANY | 2007-08-16 | — | — | US | disclosed |
| US-20070191236-A1 | cross-linking composition bistriethanolamine zirconate or tetra-triethanolamine zirconate, N,N,N',N'-tetrakis-(hydroxyisopropyl)ethylenediamine, cross-linkable polymer, water, and polyol; oil fields, hydraulic fracturing and plugging of permeable zones of subterranean formations; well bores | DORF KETAL SPECIALITY CATALYSTS, LLC | 2007-08-16 | — | — | US | disclosed |
| US-20070187642-A1 | Zirconium cross-linking composition and methods of use | E. I. DU PONT DE NEMOURS AND COMPANY | 2007-08-16 | — | — | US | disclosed |
| US-20070191233-A1 | Cross-linking composition and method of use | DORF KETAL SPECIALITY CATALYSTS, LLC | 2007-08-16 | — | — | US | disclosed |
| US-20070187101-A1 | Hydraulic fracturing methods using cross-linking composition comprising zirconium triethanolamine complex | DORF KETAL SPECIALITY CATALYSTS, LLC | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295195-A1 | ANTIMICROBIAL ORGANOSILANES | ARG1, ACMSD, AAAS | EGLN1 903/4885FFAR3 4086/4885ALDH1A1 2951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.